ei ole vielä tietystikään mitään tietoa, kehittyisikö vasta-aineita tai olisiko rokotteen sijaa.
ja tyrehtyisikö moinen itsestään...
Toistaiseksi tähän virukseen jo kuollaan ja se on uusi ihmiskunnassa, siis pandemiapotentiaalinen.
Viikonloppuna sairastuneiksi ilmoitetaan toistasataa, tosin arvioidaan että se käytännössä on lähes 2000 tapausta8 1700 nurkilla) . Hesari kirjoittaa. Koska Wuhan- New Yörk liikenne on suurta, globaalille leviämiselle on hyvät edellytykset.
https://www.hs.fi/ulkomaat/art-2000006376279.html
Taitaa alkaa taas samantapainen profylaksia kuin edellisessä pahassa SARS- purkauksessa. Sitähän on paljon Coronaviruksia, jotka eivät ole vaarallisia. tai aiheutavat vain lievää oiretta, josta parannutaan.
Täytyy taas katsoa uutta tietoa, mitä tässä on tapahtunut. Tokko muuten mitään erityistä löytyy, muuta kuin profylaksianeuvoja.
PubMed Hakusana "Novel CoV". Saan 11 pääjuurta tähän puuhun. Tällä hakusanalla tulee vanhat pahat esiin myös koska ne olivat aikoinaan myös uusia. Tämän erityisnimi on esim 2019-nCoV. Wordpress blogiin asetan tuon ensimmäisen artikkelin linkin.
Search results
Items: 11
1.
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E.
Int J Infect Dis. 2020 Jan 14;91:264-266. doi: 10.1016/j.ijid.2020.01.009. [Epub ahead of print] No abstract available.
- PMID:
- 31953166
2.
Zhang N, Wang L, Deng X, Liang R, Su M, He C, Hu L, Su Y, Ren J, Yu F, Du L, Jiang S.
J Med Virol. 2020 Jan 15. doi: 10.1002/jmv.25674. [Epub ahead of print] Review.
Respiratory tract viral infection caused by viruses or bacteria is one
of the most common diseases in human worldwide, while those caused by
emerging viruses, such as the novel coronavirus, 2019-nCoV that caused
the pneumonia outbreak in Wuhan, China most recently, have posed great
threats to global public health. Identification of the causative viral
pathogens of respiratory tract viral infections is important to select
an appropriate treatment, save people's lives, stop the epidemics, and
avoid unnecessary use of antibiotics. Conventional diagnostic tests,
such as the assays for rapid detection of antiviral antibodies or viral
antigens, are widely used in many clinical laboratories. With the
development of modern technologies, new diagnostic strategies, including
multiplex nucleic acid amplification and microarray-based assays, are
emerging. This review summarizes currently available and novel emerging
diagnostic methods for the detection of common respiratory viruses, such
as influenza virus, human respiratory syncytial virus (RSV),
coronavirus, human adenovirus (hAdV), and human rhinovirus (hRV).
Multiplex assays for simultaneous detection of multiple respiratory
viruses are also described. It is anticipated that such data will assist
researchers and clinicians to develop appropriate diagnostic strategies
for timely and effective detection of respiratory virus infections.
This article is protected by copyright. All rights reserved.
3.
Al-Amri S, Bharti R, Alsaleem SA, Al-Musa HM, Chaudhary S, Al-Shaikh AA.
J Family Med Prim Care. 2019 Feb;8(2):455-461. doi: 10.4103/jfmpc.jfmpc_336_18.Background:
Human coronaviruses (hCoV) usually cause mild to
moderate upper respiratory tract illnesses. The novel coronavirus
(nCoV), or Middle East respiratory syndrome coronavirus (MERS-CoV), is a
particular strain different from any other known hCoV with the
possibility of human and also zoonotic transmissions. The aim of the
study to assess primary health care (PHC) physicians' knowledge and
adherence regarding Saudi Ministry of Health guidelines regarding
MERS-CoV.
Free PMC Article
Free PMC Article
4.
Lin C, Ye R, Xia YL.
Genet Mol Res. 2015 Dec 2;14(4):15634-41. doi: 10.4238/2015.December.1.15.
Novel coronavirus (nCoV) belongs to the Coronaviridae family, which
includes the virus that causes SARS, or severe acute respiratory
syndrome. However, infection source, transmission route, and host of
nCoV have not yet been thoroughly characterized. In some cases, nCoV
presented a limited person-to-person transmission. Therefore, early
diagnosis of nCoV may be of importance for reducing the spread of
disease in public. Methods for nCoV diagnosis involve smear dyeing
inspection, culture identification, and real-time PCR detection, all of
which are proved highly effective. Here, we performed a meta-analysis to
evaluate the effectiveness of real-time PCR for diagnosing nCoV
infection...we propose real-time PCR as an efficient
method that offers an auxiliary support for future nCoV diagnosis.Free Article
5.
Goh GK, Dunker AK, Uversky V.
PLoS Curr.
2013 Nov 13;5. pii:
ecurrents.outbreaks.22254b58675cdebc256dbe3c5aa6498b. doi:
10.1371/currents.outbreaks.22254b58675cdebc256dbe3c5aa6498b.
A novel coronavirus, MERS-CoV (NCoV, HCoV-EMC/2012), originating from
the Middle-East, has been discovered. Incoming data reveal that the
virus is highly virulent to humans. A model that categorizes
coronaviuses according to the hardness of their shells was developed
before the discovery of MERS-CoV. Using protein intrinsic disorder
prediction, coronaviruses were categorized into three groups that can be
linked to the levels of oral-fecal and respiratory transmission
regardless of genetic proximity. Using this model, MERS-CoV is placed
into disorder group C, which consists of coronaviruses that have
relatively hard inner and outer shells. The members of this group are
likely to persist in the environment for a longer period of time and
possess the highest oral-fecal components but relatively low respiratory
transmission components. Oral-urine and saliva transmission are also
highly possible since both require harder protective shells. Results
show that disorder prediction can be used as a tool that suggests clues
to look for in further epidemiological investigations.Free PMC Article ( Sisältää kuvan struktuurista)
6.
Al-Tawfiq JA, Smallwood CA, Arbuthnott KG, Malik MS, Barbeschi M, Memish ZA.
East Mediterr Health J. 2013;19 Suppl 1:S48-54. Review. Mass gatherings are attended by an increasingly global audience and thus
raise the concern of possible acute public health risks not normally
encountered by the host population. The potential acute risks to
individual and population health include communicable diseases. The
communicable disease risks include emerging and re-emerging diseases in
host and visiting populations. In this review, we provide an overview
ofthe literature on respiratory infections at mass gatherings, then
describe the impact of novel coronavirus 2012 (nCoV), an emerging
respiratory disease virus, on the preparations for mass gathering.
Although, nCoV emerged prior to the 2012 Hajj pilgrimage season, Muslims
completed their religious duty without acquiring infections by nCoV.
Clearly, the global nature of mass gatherings and their potential risks
to international health make it imperative that research on such events
and guidelines produced for their management are relevant to diverse
contexts and are a collaborative effort between global experts.
7.
Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, Alsheikh S, Alsanouri T.
East Mediterr Health J. 2013;19 Suppl 1:S12-8.
In April 2012, an outbreak of acute respiratory illness occurred in a
public hospital in Zarqa city, in Jordan; 8 health care workers were
among the 11 people affected, 1 of who later died. The cause of the
outbreak was unknown at the time and an epidemiological investigation
including laboratory testing carried out immediately afterthe outbreak
was inconclusive. Following the discovery of novel coronavirus infection
(nCoV) in the Arabian peninsula in September 2012, stored respiratory
and serum samples of patients from this outbreak were retested and the
diagnosis of nCoV was confirmed in 2 deceased patients. This paper
describes the epidemiological findings of retrospective investigation
carried out in November 2012 and highlights the likelihood of nosocomial
transmission of nCoV infection in a health-care setting. A total of 2
laboratory-confirmed and 11 probable cases were identified from this
outbreak of whom 10 were HCWs and 2 were family members of cases.Free Article
8.
Bricaire F.
Presse Med. 2013 Jun;42(6 Pt 1):917-8. doi: 10.1016/j.lpm.2013.05.001. French. No abstract available.
9.
Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H.
Sci Rep. 2013;3:1686. doi: 10.1038/srep01686.
a combination of interferon-α2b and ribavirin, which are already
commonly used in the clinic, may be useful for patient management in the
event of future nCoV infections
- RIBAVIRIN( Rebetol Ruotsissa) ei saa käyttää yksinään vaan interferonin kanssa. Copegus ( kallis lääke, ei korvattavia Suomessa: https://www.yliopistonverkkoapteekki.fi/COPEGUS-200-mg-tabletti-kalvopaeaellysteinen-168-kpl
10.
Health Protection Agency (HPA) UK Novel Coronavirus Investigation team.
Euro Surveill. 2013 Mar 14;18(11):20427.
In February 2013, novel coronavirus (nCoV) infection was diagnosed in an
adult male in the United Kingdom with severe respiratory illness, who
had travelled to Pakistan and Saudi Arabia 10 days before symptom onset.
Contact tracing identified two secondary cases among family members
without recent travel: one developed severe respiratory illness and
died, the other an influenza-like illness. No other severe cases were
identified or nCoV detected in respiratory samples among 135 contacts
followed for 10 days.Free Article
11.
Buchholz
U, Müller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T, Bonin
F, Drosten C, Schweiger B, Wolff T, Muth D, Meyer B, Buda S, Krause G,
Schaade L, Haas W.
Euro Surveill. 2013 Feb 21;18(8). pii: 20406.On 24 October 2012, a patient with acute respiratory distress syndrome
of unknown origin and symptom onset on 5 October was transferred from
Qatar to a specialist lung clinic in Germany. Late diagnosis on 20
November of an infection with the novel Coronavirus (NCoV) resulted in
potential exposure of a considerable number of healthcare workers. Using
a questionnaire we asked 123 identified contacts (120 hospital and
three out-of-hospital contacts) about exposure to the patient.
Eighty-five contacts provided blood for a serological test using a
two-stage approach with an initial immunofluorescence assay as screening
test, followed by recombinant immunofluorescence assays and a
NCoV-specific serum neutralisation test. Of 123 identified contacts nine
had performed aerosol-generating procedures within the third or fourth
week of illness, using personal protective equipment rarely or never,
and two of these developed acute respiratory illness. Serology was
negative for all nine. Further 76 hospital contacts also tested
negative, including two sera initially reactive in the screening test.
The contact investigation ruled out transmission to contacts after
illness day 20. Our two-stage approach for serological testing may be
used as a template for similar situations.
Inga kommentarer:
Skicka en kommentar